# GARWARE HI-TECH FILMS LTD (GRWRHITECH) - COMPREHENSIVE EQUITY ANALYSIS

**Analysis Date:** February 6, 2026 (Updated)
**Current Market Price (CMP):** ‚Çπ4,260.10 (as of Feb 6, 2026 @ 9:49 AM)
**Your Average Buy Price:** ‚Çπ3,017.56
**Current Position:** +41.2% gain (‚Çπ86,978 total on 70 shares)
**Day Change:** +2.6% (‚Çπ107.90) | **Previous Close:** ‚Çπ4,152.20

---

## üî¥ LATEST UPDATE (February 6, 2026)

### Market Status
- **Stock rallying:** Up 41% from your entry despite weak Q3 results
- **Price action:** Trading UP 2.6% today at ‚Çπ4,260 (likely on UAE subsidiary news, not fundamentals)
- **52-Week Range:** ‚Çπ2,317 - ‚Çπ5,378 | Current: 21% below all-time high

### Q3 FY26 Results Released (February 5, 2026)

**‚ö†Ô∏è REVENUE DECLINED (Not Increased)**

| Metric | Q3 FY26 | YoY Change | Status |
|--------|---------|------------|--------|
| **Revenue** | ‚Çπ458.7 Cr | **-1.6%** ‚¨áÔ∏è | Declined |
| **EBITDA** | ‚Çπ86.7 Cr | **-7.4%** ‚¨áÔ∏è | Margin compressed to 18.9% |
| **PAT** | ‚Çπ55.8 Cr | **-8.3%** ‚¨áÔ∏è | Profit down faster than revenue |
| **PAT Margin** | 12.2% | Compressed | Declining margins |

**9-Month Performance (Apr-Dec 2025):**
- Revenue: ‚Çπ1,523.4 Cr (-2.4% YoY)
- EBITDA: ‚Çπ343 Cr (-8.3% YoY, margin 22.5%)
- PAT: ‚Çπ230 Cr (-9.2% YoY)

### Strategic Updates
‚úÖ Board approved wholly-owned UAE subsidiary for MENA expansion
‚úÖ Launched Garware Home Solutions (D2C business) - first studio in Mumbai
‚ö†Ô∏è Revenue and margins declining for 3 consecutive quarters

### **UPDATED RECOMMENDATION: SELL 50%, HOLD 35 shares**

**Rationale:** Stock up 41% but fundamentals deteriorating (revenue declining, margin compression). Market hasn't digested weak results yet (stock up 2.6% today on non-fundamental news). Book partial profits now, protect remaining with stop-loss.

**Action:**
- SELL 35 shares at current levels (‚Çπ1,49,103) - lock in ‚Çπ43,489 profit
- HOLD 35 shares with GTT stop-loss at ‚Çπ3,800
- Monitor Q4 results (Apr-May 2026) for margin recovery

---

## ORIGINAL ANALYSIS (January 30, 2026)

---

## EXECUTIVE SUMMARY

**RECOMMENDATION: HOLD with cautious accumulation on dips**

Garware Hi-Tech Films is a **high-quality compounder** with strong fundamentals but currently facing **near-term headwinds** (Q3 FY26 showed weakness). The stock has corrected significantly from its 52-week high of ‚Çπ5,378 (down ~44%), presenting a **potential accumulation opportunity** for long-term investors. However, given your entry at ‚Çπ3,020, you're essentially at breakeven and should **hold** while monitoring Q4 execution.

**Key Investment Thesis:**
- **Narrow-to-Wide Moat:** Backward integration, 70% market share in shrink films, only Indian SCF producer
- **Strong Financial Profile:** Debt-free, 20%+ ROCE, consistent cash generation
- **Growth Runway:** PPF expansion, TPU backward integration, D2C push in architectural films
- **Valuation:** At 22x FY25 EPS, reasonably valued vs historical 27-30x; trading below intrinsic value estimates

**Critical Risks:**
- 50% revenue exposure to US (tariff/recession risk)
- Q3 FY26 margin compression (20.1% ‚Üí 15.3% EBITDA margin)
- High valuation sensitivity to earnings miss
- Execution risk on ‚Çπ118 Cr capex for TPU line

---

## SECTION 1: BUSINESS OVERVIEW

### 1.1 Business Model

**Core Business:**  
Garware Hi-Tech Films is the **world's No.1 vertically integrated 'Chip to Film' manufacturer** of specialty polyester films. Unlike competitors, they manufacture their own raw material (polyester chips) in-house, providing cost advantages and quality control.

**Revenue Streams (FY25):**

| Segment | Approximate % | Key Products |
|---------|---------------|--------------|
| **Specialty Films (High Margin)** | ~60% | Paint Protection Films (PPF), Solar Control Films (SCF - automotive & architectural) |
| **Industrial Polyester Films** | ~40% | Shrink films (labels), thermal films, electrical insulation, metallized films |

**Geographic Mix:**
- **USA:** ~50% of revenue (KEY RISK: tariff exposure)
- **India:** ~30% (growing via D2C push)
- **Europe & RoW:** ~20%

**Customer Segments:**
- Automotive OEMs and aftermarket (PPF, SCF)
- Packaging companies (shrink labels for beverages, food)
- Industrial users (electrical insulation, graphics)
- Architecture/real estate (window films)

**Business Model Strengths:**
- **Value-added product mix increasing:** Shifted from 20% specialty to 60%+ over past 5 years
- **Recurring revenue:** Films are consumables/replacements needed
- **B2B + B2C:** Launching D2C "Garware Home Solutions" for architectural films
- **Export-heavy:** Natural hedge via currency, but US exposure is double-edged

### 1.2 Industry Structure

**Market Size & Growth:**
- **Global PPF Market:** $500M+ growing at 12-15% CAGR (premiumization of auto aftermarket)
- **Indian SCF Market:** ‚Çπ800-1,000 Cr, growing 20%+ (rising car ownership, heat rejection demand)
- **Global Shrink Films:** Mature, 4-6% CAGR, driven by packaging

**Competitive Intensity:**
- **PPF:** Fragmented globally (XPEL, 3M, LLumar leaders); Garware gaining share via innovation (colored PPF)
- **SCF:** Garware is **sole Indian producer**; globally competes with Eastman, Madico
- **Industrial Films:** Commoditized segment with Chinese competition (low margin)

**Regulatory Environment:**
- **Favorable:** No major regulatory barriers; automotive regulations driving tinting/protection demand
- **Standards:** ISO, automotive OEM certifications required (entry barrier)

### 1.3 Market Position

| Metric | Garware's Position |
|--------|-------------------|
| **Shrink Films (India)** | **70% market share** - dominant |
| **Solar Control Films (India)** | **100%** - monopoly (only producer) |
| **Paint Protection Films (Global)** | Emerging player; 5-10% share but growing |
| **Backward Integration** | **Only company globally** with chip-to-film integration for specialty films |

**Key Differentiators:**
1. **Vertical Integration:** Own polyester chip plant = 20-30% cost advantage vs peers
2. **Innovation:** 200+ products, recent launches (colored PPF, headlight protection, decorative SCF)
3. **Dual Brand:** Garware brand for India + white-label for global distributors
4. **Application Network:** 65+ Garware Application Studios (GAS), 100+ dealers for PPF installation

---

## SECTION 2: MOAT ANALYSIS

### Moat Assessment Table

| Moat Type | Rating | Evidence |
|-----------|--------|----------|
| **Brand / Pricing Power** | MODERATE | Garware brand strong in India (SCF, shrink); weak globally (white-label PPF). Recent brand push may strengthen this. |
| **Switching Costs** | WEAK-MODERATE | For B2B industrial films, switching is easy. For OEM-certified products (PPF for luxury cars), moderate switching costs exist. |
| **Network Effects** | WEAK | No network effects in film manufacturing. GAS studios create distribution network but not self-reinforcing. |
| **Cost Advantage / Scale** | **STRONG** | **Backward integration (chip plant) = 20-30% structural cost advantage.** Scale in shrink films (70% share) drives pricing power. |
| **Regulatory / License Barrier** | MODERATE | No licenses required, but OEM certifications (BMW, Mercedes) for PPF take 2-3 years to obtain. ISO, automotive standards are barriers. |
| **Intangible Assets** | MODERATE | **Patent for floatable shrink film.** R&D-driven product pipeline. Technical know-how in specialty coatings. |

### Overall Moat Rating: **NARROW-TO-WIDE**

**Moat Durability Test:**

**Q: Can a well-funded competitor replicate this in 5 years?**

**A:** Partially, but with difficulty.

- **Backward Integration (Chip Plant):** ‚úÖ Hard to replicate. Requires ‚Çπ300-500 Cr capex + 3-4 years + technical expertise. Only economically viable at scale.
- **70% Shrink Film Share:** ‚úÖ Defensible via scale economics and customer relationships.
- **Sole Indian SCF Producer:** ‚ö†Ô∏è Moderate risk. If Indian auto growth slows or Chinese/Korean entrants set up local plants, monopoly erodes. However, capital intensity deters entry.
- **PPF Technology:** ‚ùå Easier to replicate. Multiple global players exist. Garware's edge is integration + cost, not proprietary tech.

**What Could Erode the Moat?**

1. **Technological Disruption:** Shift to alternative materials (e.g., nano-coatings, ceramic protection instead of PPF)
2. **Chinese Competition:** If China dumps low-cost specialty films in India post-FTA or via grey imports
3. **Raw Material Volatility:** PET resin price spikes could compress margins despite integration
4. **Customer Consolidation:** Large automotive OEMs demanding price cuts as they consolidate suppliers
5. **Regulatory Change:** Anti-dumping duties removal, import tariff reductions

**Moat Expansion Catalysts:**
- **TPU Extrusion Line (FY27):** Will make Garware world's only fully integrated PPF producer (chip ‚Üí film ‚Üí TPU coating), deepening cost moat
- **Brand Building:** D2C push + influencer marketing could create consumer brand moat in India
- **OEM Tie-ups:** Pre-fitted PPF on new cars (currently piloting with 2 OEMs) = sticky, annuity-like revenue

### **Moat Verdict:** Currently **NARROW** moat (primarily cost advantage + scale). Progressing toward **WIDE** if TPU integration succeeds and brand gains traction.

---

## SECTION 3: FINANCIAL ANALYSIS (10-YEAR VIEW)

**Data Source:** Screener.in (Consolidated figures)  
**Fiscal Year:** March ending

### 3.1 Profitability & Returns

| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | 5Y Avg | 10Y Avg | Trend | Comment |
|--------|------|------|------|------|------|--------|---------|-------|---------|
| **ROCE (%)** | 20.6 | 13.8 | 11.5 | 12.8 | 13.1 | 14.4 | 9.7 | ‚Üë | **Excellent improvement** in FY25 as high-margin PPF scales |
| **ROE (%)** | 15.0 | 9.7 | 8.9 | 10.1 | 8.8 | 10.5 | 8.0 | ‚Üë | Still below world-class (>15%), but trending up |
| **Operating Margin (%)** | 20.9 | 16.8 | 15.8 | 18.3 | 22.1 | 18.8 | 13.5 | ‚Üë | **Strong expansion** driven by value-added products |
| **Net Profit Margin (%)** | 15.7 | 12.1 | 11.5 | 12.8 | 12.7 | 13.0 | 7.2 | ‚Üë | Among best in Indian chemicals/materials |

**FACT:** ROCE jumped from 13.8% (FY24) to 20.6% (FY25) - a sign of operational leverage kicking in.

**INTERPRETATION:** The 5Y avg ROCE of 14.4% is acceptable but not exceptional. However, the trajectory is positive, and FY25's 20.6% suggests the company is entering a higher-quality earnings phase. ROE of 15% (FY25) is at the **threshold of Buffett's "good business" criteria** (15%+).

**OPINION:** If TPU line (FY27) and PPF scale-up maintain 20%+ ROCE sustainably, this becomes a compounding machine. Risk: If China competition or US tariffs erode margins, ROCE could revert to 12-14%.

---

### 3.2 Growth

| Metric | 3Y CAGR | 5Y CAGR | 10Y CAGR | Comment |
|--------|---------|---------|----------|---------|
| **Revenue** | 16.7% | 17.9% | 9.4% | Accelerating growth (FY20-25: 18%) vs stagnant prior decade |
| **EBITDA** | 25.3% | 32.6% | 18.2% | Margin expansion + volume = compounding effect |
| **PAT** | 28.9% | 31.3% | 34.7% | **Exceptional profit growth** - ahead of revenue (positive operating leverage) |
| **EPS** | 28.9% | 31.3% | 34.7% | No equity dilution = EPS mirrors PAT growth ‚úÖ |

**FACT:** PAT grew 74% YoY in 9M FY25 vs 9M FY24 (‚Çπ253 Cr vs ‚Çπ145 Cr).

**INTERPRETATION:** The **30%+ profit CAGR (5Y/10Y)** is remarkable and rare in Indian mid-caps. Revenue CAGR accelerating from 9% (10Y) to 18% (5Y) shows successful pivot to specialty films.

**Management Guidance:**
- **FY25:** ‚Çπ2,000+ Cr revenue ‚úÖ (achieved ‚Çπ2,109 Cr)
- **FY26:** ‚Çπ2,500 Cr revenue (20% growth)
- **FY27:** 20-25% revenue CAGR continued

**Risk:** Q3 FY26 revenue declined QoQ (‚Çπ458 Cr vs ‚Çπ570 Cr in Q2), raising concerns on FY26 guidance execution. Management blames seasonality (Q3 is weak for SCF).

---

### 3.3 Balance Sheet Strength

| Metric | FY25 (Latest) | FY24 | 5Y Avg | Threshold | Status |
|--------|---------------|------|--------|-----------|--------|
| **Debt/Equity** | 0.00 | 0.00 | 0.02 | < 0.5 | ‚úÖ **Debt-free!** (‚Çπ0 borrowings as of Mar'25) |
| **Interest Coverage** | 49.4x | 22.5x | 18.2x | > 5x | ‚úÖ Extremely comfortable (almost no debt) |
| **Current Ratio** | 2.68 | 2.43 | 2.10 | > 1.5 | ‚úÖ Healthy working capital |
| **Cash Conversion Cycle (days)** | 68 | 67 | 58 | Declining preferred | ‚ö†Ô∏è Stable but not improving; inventory days high (116) |

**FACT:** Company ended FY25 with **‚Çπ643 Cr in cash/investments** vs ‚Çπ363 Cr in FY24.

**INTERPRETATION:** **Fortress balance sheet.** Zero debt, rising cash reserves, and 2.7x current ratio = financial flexibility to fund ‚Çπ118 Cr TPU capex + dividends without external financing.

**OPINION:** Cash hoard is a double-edged sword. Good for downturns, but ROE could improve if deployed aggressively (buybacks, M&A, higher capex). Management's conservative stance is prudent given US exposure risk.

---

### 3.4 Cash Flow Quality

| Metric | FY25 | FY24 | FY23 | FY22 | 5Y Avg | Comment |
|--------|------|------|------|------|--------|---------|
| **Operating Cash Flow (‚Çπ Cr)** | 330 | 172 | 218 | 172 | 210 | Strong FY25 |
| **Free Cash Flow (‚Çπ Cr)** | 291* | 218** | 50 | 31 | 120 | *After maintenance capex est. |
| **FCF/PAT (%)** | 88% | 107% | 30% | 19% | 61% | FY24-25 excellent; prior years lumpy due to capex |
| **Capex/CFO (%)** | 12% | -27% | 77% | 82% | 49% | FY25: Low capex year; FY26: ‚Çπ118 Cr TPU will spike this |
| **FCF Yield (on ‚Çπ7,000 Cr MCap)** | 4.2% | 3.1% | 0.7% | 0.4% | 1.7% | Improving; 4%+ is respectable |

**FACT:** In 9M FY25, company generated ‚Çπ192 Cr FCF at ‚Çπ11,363 Cr market cap = 1.7% **non-annualized** FCF yield.

**INTERPRETATION:** Cash conversion improving dramatically. FY24-25's FCF/PAT >100% indicates asset-light growth phase. However, ‚Çπ118 Cr TPU capex (announced Q3 FY25) + likely PPF line expansion will absorb ‚Çπ150-200 Cr in FY26-27.

**OPINION:** High-quality cash generation. Unlike many Indian industrials, Garware converts profits to cash efficiently (no working capital bloat). FCF should remain strong even with growth capex due to ~‚Çπ650 Cr cash cushion.

---

### 3.5 Capital Allocation Track Record

**Reinvestment Rate √ó ROCE = Intrinsic Growth Rate:**
- **FY25 Reinvestment:** ~40% (‚Çπ60 Cr capex / ‚Çπ150 Cr after-tax earnings available for reinvestment)
- **ROCE:** 20.6%
- **Intrinsic Growth Rate:** 40% √ó 20.6% = **~8%**
- **Actual Growth (FY25):** 25% (revenue), 63% (PAT)

**Gap Explanation:** Growth exceeded intrinsic rate due to (a) operating leverage, (b) margin expansion, (c) under-earning in prior years.

**Dividend Policy:**
| FY | DPS (‚Çπ) | Payout Ratio | Yield @ CMP |
|----|---------|--------------|-------------|
| FY25 | 12 | 8% | 0.4% |
| FY24 | 10 | 11% | 0.33% |
| FY23 | 10 | 14% | 0.33% |

**FACT:** Consistent dividend (‚Çπ10-12 per share) but **low payout ratio (8-14%).**

**INTERPRETATION:** Management prioritizes **reinvestment over dividends** - appropriate for growth phase. Yield of 0.4% is negligible.

**Buybacks:** None to date.

**M&A History:**
- **FY22:** Merged Garware Chemicals Ltd (DMT plant) into main entity
- **FY25:** Set up US/UK subsidiaries for global sales
- **FY26:** Announced UAE subsidiary (MENA expansion)

**INTERPRETATION:** No major acquisitions; focus on **organic growth.** Recent subsidiaries are sales entities (low risk, high leverage).

**Equity Dilution:** Zero. Share count unchanged at 2.32 Cr shares (‚Çπ23 Cr equity capital @ ‚Çπ10 FV) over past decade.

**SCORE:** **GOOD (not yet EXCELLENT)**

**Why not EXCELLENT?**
- Low dividend yield frustrates income investors (but reinvestment discipline is good)
- No buybacks despite strong FCF (opportunity cost)
- Could deploy cash more aggressively (M&A in adjacent segments?)

**Why GOOD?**
- Zero dilution ‚úÖ
- Reinvesting at 20%+ ROCE ‚úÖ
- Debt-free despite growth ‚úÖ
- Conservative M&A (avoiding empire-building) ‚úÖ

---

## SECTION 4: MANAGEMENT & GOVERNANCE

### 4.1 Promoter & Ownership

| Factor | Current | Red Flag Threshold | Status | Comment |
|--------|---------|-------------------|--------|---------|
| **Promoter Holding** | 60.73% | < 40% caution | ‚úÖ | Stable; **Garware family** (Dr. S.B. Garware, Monika Garware) |
| **Promoter Pledge** | 0% | > 10% red flag | ‚úÖ **Excellent** | Zero pledge consistently |
| **Shareholding Trend (2Y)** | Flat | Declining concerning | ‚úÖ | No stake sales; steady at 60.7% |

**FACT:** Promoters have **not sold a single share** in past 5 years despite stock rallying 6x.

**INTERPRETATION:** Strong alignment with minority shareholders. Zero pledge = financial stability of promoters.

---

### 4.2 Related Party Transactions (RPTs)

**FY24 Annual Report Analysis:**
- **RPTs:** Leases for office space, managerial remuneration to directors
- **Arms-Length:** Auditors confirmed RPTs are at market rates
- **Materiality:** < 2% of revenue
- **Status:** ‚úÖ No red flags

---

### 4.3 Auditor & Compliance

| Factor | Status | Comment |
|--------|--------|---------|
| **Auditor** | Deloitte Haskins & Sells LLP | Big-4 auditor; no changes in 5+ years ‚úÖ |
| **Audit Opinion** | Unqualified (Clean) for FY24 | ‚úÖ |
| **Key Audit Matters** | Revenue recognition, inventory valuation | Standard for manufacturing |
| **Historical Red Flags** | None | ‚úÖ |

**FACT:** Deloitte has been auditor since pre-2015; **no auditor changes = positive signal.**

---

### 4.4 Board Independence & Quality

| Parameter | Current | Comment |
|-----------|---------|---------|
| **Independent Directors** | 4 out of 8 | 50% - meets SEBI minimum (33%+) ‚úÖ |
| **Board Diversity** | 2 women directors (Monika Garware + 1 independent) | ‚úÖ |
| **Board Meetings** | 5 in FY24 | Standard ‚úÖ |
| **Audit Committee** | 100% independent | ‚úÖ |
| **Nomination & Remuneration Committee** | Majority independent | ‚úÖ |

**INTERPRETATION:** Board structure complies with regulations. However, **true independence is questionable** in family-run Indian firms - independent directors rarely challenge promoters.

---

### 4.5 Management Compensation

| Executive | FY24 Compensation | % of PAT | Justified? |
|-----------|-------------------|----------|------------|
| **Dr. S.B. Garware** (CMD) | ‚Çπ3.2 Cr | 1.6% | ‚úÖ Reasonable |
| **Monika Garware** (Vice Chairperson & JMD) | ‚Çπ3.0 Cr | 1.5% | ‚úÖ Reasonable |
| **Total Key Managerial Personnel** | ‚Çπ8.5 Cr | 4.2% | ‚úÖ Conservative |

**INTERPRETATION:** Compensation is **reasonable and aligned** with performance. Not excessive like some family businesses (where promoters take 20%+ of PAT as salary).

---

### 4.6 Equity Dilution & Capital History

| Year | Equity Capital (‚Çπ Cr) | Shares (Cr) | Comment |
|------|----------------------|-------------|---------|
| FY15-FY25 | 23 | 2.32 | **Zero dilution** ‚úÖ |
| FY14 | 23 | 2.32 | 5:1 stock split in FY14 (post-split shares) |

**INTERPRETATION:** **No equity dilution in 10+ years.** Growth funded via internal accruals = shareholder-friendly.

---

### 4.7 Insider Transactions (Last 6 Months)

**Promoter/Director Transactions:** None reported (based on latest filings).

**INTERPRETATION:** Neutral. No buying (shows no undervaluation signal from insiders) but also no selling (no red flag).

---

### 4.8 Litigation & Regulatory Issues

**BSE/NSE Filings Review:**
- **Material Litigation:** None pending per FY24 annual report
- **Tax Disputes:** Routine income tax appeals (‚Çπ10-15 Cr disputed) - standard
- **Labor Issues:** None disclosed
- **Environmental Compliance:** No penalties or notices

**INTERPRETATION:** ‚úÖ **Clean record.** No major regulatory or legal overhang.

---

### 4.9 Red Flags Checklist

| Red Flag | Present? | Evidence |
|----------|----------|----------|
| Promoter stake falling | ‚ùå | Stable at 60.7% |
| Pledged shares | ‚ùå | 0% pledged |
| Frequent equity dilution | ‚ùå | Zero dilution in 10Y |
| Auditor changes | ‚ùå | Deloitte since 2015+ |
| Qualified audit opinions | ‚ùå | Clean opinions |
| Material RPTs | ‚ùå | < 2% of revenue, arms-length |
| High management compensation | ‚ùå | 4% of PAT |
| Promoter selling at highs | ‚ùå | No sales |
| Complex corporate structure | ‚ùå | Simple: Parent + 3 foreign subsidiaries (sales entities) |
| Regulatory penalties | ‚ùå | None |

**Verdict:** ‚úÖ **Clean governance. No major red flags.**

---

### 4.10 Management Quality Score: **HIGH**

**Strengths:**
- Zero pledge, zero dilution, debt-free = **financial prudence** ‚úÖ
- Executed strategy shift (commodity ‚Üí specialty films) successfully ‚úÖ
- Transparent communication (concalls, investor presentations) ‚úÖ
- Long-term focus (20% CAGR guidance through FY27) ‚úÖ

**Weaknesses:**
- **Family-dominated:** 2 of 4 executive roles held by Garwares (succession risk)
- **Conservative cash deployment:** ‚Çπ650 Cr cash earning low returns (could buy back shares or M&A)
- **US exposure management:** Insufficient hedging disclosed for 50% revenue exposure

---

### Governance Risk: **LOW**

---

## SECTION 5: VALUATION ANALYSIS

### 5.1 Absolute Valuation - Historical Multiples

| Metric | Current (Feb'26) | 5Y Median | 10Y Median | Premium/Discount |
|--------|------------------|-----------|------------|------------------|
| **P/E** | 22.3x* | 29.0x | 24.0x | **-23% to 5Y** / -7% to 10Y |
| **EV/EBITDA** | 16.8x | 18.5x | 15.0x | -9% to 5Y / +12% to 10Y |
| **P/B** | 2.9x | 3.5x | 2.2x | -17% to 5Y / +32% to 10Y |
| **P/FCF** | 24.0x | 35.0x | N/A (neg FCF prior) | -31% to 5Y |
| **PEG** | 0.9x** | 1.2x | 1.5x | **Attractive** (< 1.0) |

*Based on CMP ‚Çπ3,012; FY25 EPS ‚Çπ135 (annualized from 9M data)  
**PEG = P/E √∑ Expected Growth Rate (22.3 √∑ 25% = 0.9x)

**FACT:** Stock trading at **23% discount to 5Y median P/E** (29x). At peak (Dec'24), it touched 38x P/E (‚Çπ5,378).

**INTERPRETATION:**
- **Cheap vs Recent History:** Current 22x P/E is at lower end of 5Y range (20-40x).
- **PEG < 1.0 = Undervalued:** If 20-25% growth sustains, PEG of 0.9x suggests upside.
- **P/B of 2.9x:** Reasonable for 15% ROE (P/B = ROE √ó P/E √∑ 100; implied = 15% √ó 22 √∑ 100 = 3.3x).

---

### 5.2 Relative Valuation vs Peers

**Comparable Companies:** Polyplex Corp, Uflex Ltd, Cosmo Films, SRF Ltd (polyester/specialty films segment)

| Company | CMP | P/E (TTM) | EV/EBITDA | ROCE (%) | Revenue Growth (3Y CAGR) | Comment |
|---------|-----|-----------|-----------|----------|--------------------------|---------|
| **Garware Hi-Tech** | ‚Çπ3,012 | 22.3x | 16.8x | 20.6 | 17% | **Target** |
| Polyplex Corp | ‚Çπ1,450 | 18.0x | 12.0x | 12.0 | 8% | Commodity BOPET; lower margin |
| Uflex Ltd | ‚Çπ450 | 25.0x | 14.0x | 11.0 | 5% | Diversified packaging; debt-heavy |
| Cosmo Films | ‚Çπ1,250 | 20.0x | 13.0x | 15.0 | 10% | BOPP films; better ROE than most |
| SRF Ltd (Films) | ‚Çπ2,800 | 35.0x | 22.0x | 18.0 | 12% | Specialty chemicals + films; premium valuations |

**INTERPRETATION:**
- **Garware trades at PREMIUM vs commodity film peers** (Polyplex, Uflex) due to higher ROCE and growth.
- **Slight DISCOUNT vs SRF** (35x PE for SRF vs 22x for Garware) - justified as SRF is larger, more diversified.
- **ROCE of 20.6% = Best-in-class** among pure-play film companies.

**Relative Value Verdict:** **Fairly valued** within peer group. Premium to commodity players is justified; discount to SRF reflects smaller scale + higher US concentration risk.

---

### 5.3 Intrinsic Value Estimate - DCF Method

**Methodology:** Free Cash Flow to Firm (FCFF) discounted at WACC.

**Assumptions:**
| Parameter | Value | Justification |
|-----------|-------|---------------|
| **Base Year FCF (FY25)** | ‚Çπ290 Cr | Actual FY25 OCF ‚Çπ330 Cr - Capex ‚Çπ40 Cr |
| **Growth Rate (Y1-5)** | 20% | Management guidance 20-25%; conservative 20% |
| **Growth Rate (Y6-10)** | 12% | Mature phase; India GDP + 3-4% |
| **Terminal Growth** | 6% | India long-term GDP growth |
| **Cost of Equity (Ke)** | 14% | Risk-free 7% + Beta 0.31 √ó 7% equity risk premium = ~9.2%, rounded to 14% for conservatism |
| **WACC** | 14% | Debt = 0; WACC = Ke |

**DCF Calculation (Simplified):**
- **PV of Y1-10 Cash Flows:** ‚Çπ3,200 Cr (discounted at 14%)
- **Terminal Value:** FCF Y11 (‚Çπ800 Cr) / (14% - 6%) = ‚Çπ10,000 Cr; PV = ‚Çπ2,700 Cr
- **Enterprise Value:** ‚Çπ3,200 + ‚Çπ2,700 = ‚Çπ5,900 Cr
- **Less: Net Debt:** -‚Çπ650 Cr (net cash)
- **Equity Value:** ‚Çπ6,550 Cr
- **Per Share Value:** ‚Çπ6,550 Cr / 2.32 Cr shares = **‚Çπ2,823**

**Intrinsic Value Range (Sensitivity Analysis):**

| Scenario | Growth (Y1-5) | WACC | Intrinsic Value |
|----------|---------------|------|-----------------|
| **Bear** | 15% | 16% | ‚Çπ2,200 |
| **Base** | 20% | 14% | ‚Çπ2,823 |
| **Bull** | 25% | 12% | ‚Çπ3,800 |

---

### 5.4 Reverse DCF Analysis

**What growth is market pricing at CMP ‚Çπ3,012?**

- At 14% WACC, CMP ‚Çπ3,012 implies **18-19% FCF CAGR (Y1-10).**
- This is **slightly below** management's 20-25% revenue guidance.

**INTERPRETATION:** Market is **mildly skeptical** of sustained 20%+ growth, likely due to:
1. Q3 FY26 miss (sequential revenue decline)
2. US recession/tariff fears
3. High valuation sensitivity in mid-caps

---

### 5.5 Valuation Verdict

| Zone | Price Range | CMP Status | Action |
|------|-------------|------------|--------|
| **Attractive (>25% MoS)** | < ‚Çπ2,100 | Below | **Aggressive Buy** |
| **Fair Value (10-25% MoS)** | ‚Çπ2,100 - ‚Çπ2,550 | Below | **Accumulate on dips** |
| **Fully Valued (0-10% MoS)** | ‚Çπ2,550 - ‚Çπ2,820 | **HERE** | **Hold / Nibble** |
| **Overvalued** | > ‚Çπ2,820 | Below | Book Profits |

**Current Price (‚Çπ3,012) vs Base Intrinsic (‚Çπ2,823) = +7% premium.**

**Assessment:**
- **Slightly overvalued on DCF** but within margin of error.
- **Attractive on PEG (0.9x)** and historical P/E discount.
- **Fair vs peers.**

**Verdict:** **FAIRLY VALUED WITH SLIGHT UPSIDE.** At your entry of ‚Çπ3,020, you're at **fair value** - neither cheap nor expensive. Stock offers **asymmetric risk-reward** if FY26 execution is strong (upside to ‚Çπ4,000+), but downside to ‚Çπ2,200-2,400 if growth disappoints.

---

## SECTION 6: TECHNICAL ANALYSIS

**Note:** Technical analysis is secondary overlay. Fundamentals drive long-term returns.

### 6.1 Trend Analysis (As of Early Feb 2026)

| Timeframe | Trend | Key Levels | Comment |
|-----------|-------|------------|---------|
| **Long-term (200 DMA)** | Down | 200 DMA: ~‚Çπ3,800 | Stock below 200 DMA; bearish long-term |
| **Medium-term (50 DMA)** | Sideways | 50 DMA: ~‚Çπ3,200 | Consolidating after correction |
| **Short-term (20 DMA)** | Up | 20 DMA: ~‚Çπ2,950 | Recent bounce from Jan lows |

**Support Levels:**
- **Immediate:** ‚Çπ2,900 (Jan'26 low)
- **Strong:** ‚Çπ2,300-2,400 (52-week low Oct'25)

**Resistance Levels:**
- **Immediate:** ‚Çπ3,200-3,300 (50 DMA)
- **Strong:** ‚Çπ3,800-4,000 (200 DMA + psychological)
- **Major:** ‚Çπ5,378 (52-week high Dec'24)

---

### 6.2 Technical Indicators

| Indicator | Current Value | Signal | Interpretation |
|-----------|---------------|--------|----------------|
| **RSI (14)** | ~48 | Neutral | Not oversold (<30) nor overbought (>70); neutral zone |
| **MACD** | Bearish crossover recently | Bearish | MACD below signal line; downtrend intact |
| **Volume** | Below avg | Distribution | Low volumes = weak hands exiting; no strong buying |
| **52W Range** | ‚Çπ2,317 - ‚Çπ5,378 | Mid-range | CMP at ~44% from high, 30% above low |
| **Distance from 52W High** | -44% | Correction territory | Significant drawdown from peak |
| **Distance from 52W Low** | +30% | Off lows | Bounced from Oct'25 crash lows |

**Chart Patterns:**
- **Descending Triangle (Nov'25 - Jan'26):** Bearish pattern; broke down to ‚Çπ2,900 in Jan.
- **Potential Double Bottom:** If ‚Çπ2,900 holds and stock reclaims ‚Çπ3,200, could form reversal.

---

### 6.3 Technical Verdict

**Trend Alignment:** **UNFAVORABLE** for momentum buyers.

- Stock in **correction phase** (down 44% from high).
- Below 200 DMA = long-term downtrend.
- MACD bearish = no trend reversal yet.

**For Long-Term Investors (Your Case):**
- **Entry at ‚Çπ3,020:** You bought near resistance; now stuck in consolidation.
- **Risk:** If ‚Çπ2,900 breaks, next support is ‚Çπ2,400 (another 20% downside).
- **Opportunity:** If ‚Çπ3,200 reclaimed with volume, could run to ‚Çπ3,800-4,000.

**Suggested Action (Technical Overlay):**
- **Hold** current position (at ‚Çπ3,020).
- **Stop-Loss (for traders):** ‚Çπ2,750 (breach invalidates consolidation).
- **Accumulation Zone:** ‚Çπ2,400-2,600 (if stock dips again).
- **Target (12-18M):** ‚Çπ4,000-4,500 (if fundamentals deliver).

**Entry Zone for Fresh Buyers:** **‚Çπ2,600-2,800** (10-15% below CMP; near 200 DMA support).

---

## SECTION 7: RISK ANALYSIS

### 7.1 Risk Matrix

| Risk Category | Specific Risks | Severity | Probability | Mitigation/Monitoring |
|---------------|----------------|----------|-------------|----------------------|
| **Business/Competitive** | - Chinese dumping of films in India<br>- PPF competition from 3M/XPEL<br>- Tech disruption (ceramic coating > PPF) | Medium | Medium | **Monitor:** Import data, competitor financials, new tech adoption<br>**Mitigation:** TPU integration, brand building |
| **Regulatory/Trade** | - **US tariffs on Indian exports**<br>- Anti-dumping duty changes<br>- Automotive emission norms impacting car sales | **HIGH** | **HIGH** | **Monitor:** Trump admin trade policy, US-India FTA talks<br>**Mitigation:** Diversify to MENA, Europe; grow India to 50% revenue |
| **Financial/Leverage** | - Raw material inflation (PET resin)<br>- FX volatility (50% export revenue) | Medium | Medium | **Monitor:** Crude prices, USD-INR<br>**Mitigation:** Backward integration hedges PET risk; natural FX hedge via imports |
| **Governance/Promoter** | - Family succession risk<br>- Key-person risk (Dr. S.B. Garware) | Low | Low | **Monitor:** Promoter transactions, leadership changes<br>**Mitigation:** Monika Garware as JMD = succession in place |
| **Valuation** | - **High P/E (22x) leaves no room for error**<br>- FY26 guidance miss could crash stock 30%+ | **HIGH** | Medium | **Monitor:** Quarterly results vs guidance<br>**Mitigation:** Entry only at <‚Çπ2,600 or stagger buying |
| **Macro/Sectoral** | - US recession impacting 50% revenue<br>- Auto slowdown (PPF/SCF demand)<br>- Packaging degrowth (shrink films) | Medium | Medium | **Monitor:** US PMI, India auto sales, EV adoption<br>**Mitigation:** Diversified product mix, D2C push |

---

### 7.2 Key Monitorables (What Could Change the Thesis?)

**Track these quarterly:**

1. **Revenue Growth vs Guidance:**
   - **Bull Case:** Achieves ‚Çπ2,500 Cr in FY26 (20% growth) ‚Üí Stock re-rates to 28-30x PE = ‚Çπ4,200+
   - **Bear Case:** Misses ‚Çπ2,300 Cr (<10% growth) ‚Üí De-rates to 18x PE = ‚Çπ2,400

2. **EBITDA Margins:**
   - **Target:** Maintain 22-25% (guided)
   - **Risk:** Q3 FY26 was 15.3% (vs 20%+ in H1) ‚Üí If Q4 doesn't recover, margin expansion story breaks

3. **US Exposure:**
   - **Key:** Watch for tariff announcements, customer concentration
   - **Action:** If US revenue drops >10% YoY, revisit thesis

4. **TPU Line Execution:**
   - **Expected:** Commissioning by Oct'26; margin expansion in FY27
   - **Risk:** Delays or technical issues ‚Üí Postpones margin benefits

5. **Promoter Actions:**
   - **Positive Signal:** Promoter buying at <‚Çπ2,500 = strong conviction
   - **Negative Signal:** Stake reduction or pledging = red flag

---

## SECTION 8: INVESTMENT THESIS

### 8.1 Bull Case (Price Target: ‚Çπ4,500-5,000 | 50-65% Upside)

**What Goes Right:**

1. **FY26 Guidance Achieved:** Revenue hits ‚Çπ2,500 Cr (20% growth), PAT ‚Çπ380-400 Cr (15-20% growth) ‚Üí EPS ‚Çπ165 ‚Üí At 27x PE (5Y avg) = ‚Çπ4,455.

2. **US Trade War Avoided:** Indo-US FTA or status quo on tariffs ‚Üí Removes key overhang; stock re-rates.

3. **TPU Line Success:** Commissions on time (Oct'26), drives EBITDA margin to 28% in FY27 ‚Üí ROCE sustains >20% ‚Üí Multiple expansion to 30x PE.

4. **OEM PPF Tie-Ups:** Pre-fitted PPF on 2-3 major OEMs (e.g., Tata, Mahindra) ‚Üí Opens ‚Çπ200-300 Cr annuity revenue stream by FY28.

5. **D2C Breakout:** Garware Home Solutions scales to 200+ studios by FY27 ‚Üí Builds consumer brand ‚Üí Premium valuations like Asian Paints (40-50x PE).

6. **Market Share Gains:** SCF/PPF global penetration accelerates ‚Üí Revenue CAGR sustains 25% through FY27 ‚Üí Stock compounds at 30-40% annually.

**Catalysts:**
- Strong Q4 FY25 & Q1 FY26 results (Mar-Jun'26)
- US Fed rate cuts ‚Üí Risk-on for mid-caps
- Positive Trump-Modi trade deal

---

### 8.2 Base Case (Price Target: ‚Çπ3,500-3,800 | 15-25% Upside)

**Most Likely Scenario:**

1. **Moderate Growth:** FY26 revenue ‚Çπ2,300-2,400 Cr (10-15% growth) due to Q3 weakness + US slowdown ‚Üí PAT ‚Çπ340-360 Cr ‚Üí EPS ‚Çπ150.

2. **Margins Stabilize:** EBITDA margins recover to 20-22% (from Q3's 15%) as Q4 seasonality improves ‚Üí Full-year FY26 margin ~21%.

3. **Valuation Re-Rating:** At ‚Çπ3,500, stock trades at 23x FY26 EPS (‚Çπ150) ‚Üí In line with 10Y median ‚Üí Fair value maintained.

4. **TPU Line Delayed:** Commissioning slips to Q1 FY27 (vs Oct'26) ‚Üí Margin benefits pushed out but thesis intact.

5. **US Exposure:** No major tariff hikes, but growth slows to 5-8% in US market ‚Üí India/MENA compensate partially.

6. **Dividend Bump:** Company raises DPS to ‚Çπ15-18 (vs ‚Çπ12 in FY25) as payout ratio increases to 12-15% ‚Üí Supports stock via yield.

**Catalysts:**
- Steady-state execution (no surprises)
- Gradual shift to 40% India, 40% US, 20% RoW by FY27

---

### 8.3 Bear Case (Price Target: ‚Çπ2,000-2,400 | 20-35% Downside)

**What Goes Wrong:**

1. **FY26 Guidance Miss:** Revenue <‚Çπ2,200 Cr (<5% growth) due to US recession + auto slowdown ‚Üí PAT ‚Çπ280-300 Cr ‚Üí EPS ‚Çπ125 ‚Üí At 18x PE (de-rating) = ‚Çπ2,250.

2. **US Tariffs:** 10-15% import duties on Indian films ‚Üí Erodes competitiveness; US revenue declines 20% ‚Üí Overall revenue growth stalls.

3. **Margin Compression:** Raw material inflation (PET resin up 20%) + price competition ‚Üí EBITDA margin falls to 16-18% ‚Üí ROCE drops to 14-16% ‚Üí Growth story questioned.

4. **TPU Line Failure:** Technical issues, cost overruns, or commissioning delayed beyond FY27 ‚Üí Capex turns unproductive ‚Üí ROE deteriorates.

5. **Chinese Competition:** Subsidized Chinese specialty films enter India aggressively ‚Üí Garware loses market share in shrink films (70% ‚Üí 50%) + pricing pressure.

6. **Governance Shock:** Promoter pledging, related-party issues, or key management exit ‚Üí Stock crashes 40%+ (trust loss).

**Catalysts:**
- US enters recession (Q2-Q3 2026)
- Trump admin imposes broad tariffs on India
- China floods market with cheap films
- Quarterly result miss (Q4 FY25 or Q1 FY26)

---

### 8.4 Scenario Probability Weights

| Scenario | Probability | Target | Expected Value |
|----------|-------------|--------|----------------|
| Bull | 25% | ‚Çπ4,750 | ‚Çπ1,188 |
| Base | 50% | ‚Çπ3,650 | ‚Çπ1,825 |
| Bear | 25% | ‚Çπ2,200 | ‚Çπ550 |
| **Expected Value** | | | **‚Çπ3,563** |

**Expected Return @ CMP ‚Çπ3,012:** +18% (12-18 months)

---

## SECTION 9: FINAL RECOMMENDATION

### 9.1 Scorecard

| Parameter | Assessment | Weight | Weighted Score |
|-----------|------------|--------|----------------|
| **Moat Quality** | NARROW (progressing to WIDE) | 25% | 15/25 |
| **Financial Strength** | STRONG | 25% | 22/25 |
| **Management Quality** | HIGH | 20% | 16/20 |
| **Valuation** | FAIR | 20% | 12/20 |
| **Technical Setup** | UNFAVORABLE | 10% | 3/10 |
| **TOTAL SCORE** | | 100% | **68/100** |

**Interpretation:** Score of 68/100 = **HOLD/ACCUMULATE on dips** (not a screaming buy, but quality compounder).

---

### 9.2 RECOMMENDATION: **HOLD** ‚úã

**For Your Position (Avg Buy: ‚Çπ3,020):**

**DO NOT SELL.** You're at fair value (breakeven). Stock offers:
- **15-25% upside** (12-18M) in base case
- **50%+ upside** in bull case
- **20-35% downside** in bear case

**Risk-Reward:** Asymmetric (~2:1 upside:downside).

**Action:**
1. **Hold** current position.
2. **Do NOT average up** at ‚Çπ3,200+.
3. **Consider averaging down** ONLY if:
   - Stock dips to ‚Çπ2,400-2,600 (15-20% below CMP) **AND**
   - Q4 FY25 results are strong (revenue >‚Çπ550 Cr, EBITDA margin >20%)
   - US tariff fears subside

4. **Set Mental Stop-Loss:** If stock breaks ‚Çπ2,200 with volume on bad news (e.g., US tariff, guidance cut), **reassess thesis.** Don't blindly hold to zero.

5. **Review Quarterly:** Post Q4 FY25 (May'26) and Q1 FY26 (Aug'26) results, revisit recommendation.

---

### 9.3 For Fresh Investors

**Recommendation:** **ACCUMULATE on dips to ‚Çπ2,400-2,600.**

**Why Not Buy Now?**
- CMP ‚Çπ3,012 offers modest 18% expected return (vs 30%+ at ‚Çπ2,400).
- Technical setup unfavorable (below 200 DMA).
- Q3 FY26 weakness raises execution concerns.

**Suggested Strategy:**
- **20% allocation** at ‚Çπ2,600 (if dips)
- **30% allocation** at ‚Çπ2,400 (panic sell-off)
- **50% allocation** at ‚Çπ2,200 (bear case realized, but fundamentals intact)

**Position Sizing:** Max 5-7% of equity portfolio (mid-cap, single-product concentration risk).

---

### 9.4 Price Targets (12-18 Month Horizon)

| Scenario | Target | Timeframe | Upside/Downside from CMP (‚Çπ3,012) | Probability |
|----------|--------|-----------|-----------------------------------|-------------|
| **Bear** | ‚Çπ2,200 | 6-12M | -27% | 25% |
| **Base** | ‚Çπ3,650 | 12-18M | +21% | 50% |
| **Bull** | ‚Çπ4,750 | 18-24M | +58% | 25% |

**Expected Target (Probability-Weighted):** ‚Çπ3,563 (+18% from CMP)

---

### 9.5 Exit Strategy

**When to Sell:**

1. **Profit Booking:**
   - **30% of position** at ‚Çπ4,200-4,500 (40-50% gain from your entry)
   - **Trailing stop-loss** at 15% below peak thereafter

2. **Thesis Breaks:**
   - US revenue declines >15% YoY for 2 consecutive quarters
   - ROCE falls below 15% for 2 consecutive years
   - Promoter pledging >10% or stake reduction
   - Debt-to-equity rises above 0.5

3. **Valuation Extremes:**
   - If P/E exceeds 40x (bubble territory) ‚Üí Book 50%+ profits
   - If P/E falls below 15x (deep value) ‚Üí Re-evaluate for doubling down or broken thesis

---

## SECTION 10: QUICK REFERENCE CARD

```
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
COMPANY:           Garware Hi-Tech Films Ltd (GRWRHITECH)
SECTOR:            Specialty Chemicals - Polyester Films
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
MOAT:              NARROW (progressing to WIDE)
ROCE (5Y):         14.4% | FY25: 20.6% ‚≠ê
DEBT/EQUITY:       0.00 (Debt-Free) ‚úÖ
FCF YIELD:         4.2% (FY25)
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
VALUATION
P/E (Current):     22.3x
10Y Median P/E:    24.0x (7% discount)
PEG:               0.9x (attractive for 25% growth)
INTRINSIC VALUE:   ‚Çπ2,200 (Bear) - ‚Çπ3,800 (Bull)
                   Base: ‚Çπ2,823
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
PRICE DATA
CMP (Jan'30'26):   ‚Çπ3,012
Your Entry:        ‚Çπ3,020 (0.26% loss)
52W Range:         ‚Çπ2,317 - ‚Çπ5,378
Distance from High: -44% (correction territory)
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
MARGIN OF SAFETY:  -7% (slightly overvalued vs base DCF)
                   BUT attractive on PEG & historical P/E
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
RECOMMENDATION:    HOLD ‚úã (for existing position)
                   ACCUMULATE at ‚Çπ2,400-2,600 (fresh buyers)
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
ENTRY ZONE:        ‚Çπ2,400 - ‚Çπ2,600 (20% upside to base target)
CURRENT ZONE:      ‚Çπ3,000 - ‚Çπ3,200 (hold, don't add)
STOP LOSS:         ‚Çπ2,200 (thesis invalidation / bear case)
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
TARGETS (12-18M)
Bear:              ‚Çπ2,200 (-27%)
Base:              ‚Çπ3,650 (+21%)
Bull:              ‚Çπ4,750 (+58%)
Expected (Wt Avg): ‚Çπ3,563 (+18%)
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
KEY RISK:          50% US revenue exposure; tariff threat üö®
                   Q3 FY26 margin drop (20% ‚Üí 15%)
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
KEY CATALYST:      TPU line (FY27) ‚Üí margin expansion to 25%+
                   OEM PPF tie-ups ‚Üí annuity revenue
                   US-India FTA ‚Üí removes tariff overhang
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
QUALITY SCORE:     68/100 (GOOD, not yet GREAT)
PROMOTER HOLDING:  60.7% | Pledge: 0% ‚úÖ
DIVIDEND YIELD:    0.4% (low; growth stock)
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
NEXT EARNINGS:     Q4 FY25: Expected Feb 2026 ‚è≥
                   Watch for: Revenue >‚Çπ550 Cr, Margin >20%
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
```

---

## LATEST EARNINGS UPDATE (Q3 FY26 - Dec 2025) - CONFIRMED RESULTS

### Key Highlights (Released Feb 5, 2026):
- **Revenue:** ‚Çπ458.7 Cr (**-1.6% YoY**) ‚ö†Ô∏è
- **EBITDA:** ‚Çπ86.7 Cr (**-7.4% YoY**) - Margin compressed to **18.9%** ‚ö†Ô∏è
- **PAT:** ‚Çπ55.8 Cr (**-8.3% YoY**) ‚ö†Ô∏è
- **PAT Margin:** 12.2% (compressed from prior quarters)

### 9-Month Performance (Apr-Dec 2025):
- **Revenue:** ‚Çπ1,523.4 Cr (**-2.4% YoY**)
- **EBITDA:** ‚Çπ343 Cr (**-8.3% YoY**) with margin 22.5%
- **PAT:** ‚Çπ230 Cr (**-9.2% YoY**) with margin 15.1%

### üö© Red Flags Identified:
1. **Revenue declining** - NOT growing as expected
2. **Margin compression** - EBITDA margin 18.9% vs historical 22%+
3. **Profit declining faster than revenue** - operational inefficiency signal
4. **3-quarter negative trend** - consistent deterioration

### Strategic Initiatives (Positive):
‚úÖ **UAE Subsidiary:** Board approved wholly-owned subsidiary for MENA market expansion
‚úÖ **D2C Launch:** Garware Home Solutions - first studio opened in Mumbai
‚úÖ **Product Focus:** Architectural films for direct-to-consumer market

### Market Reaction:
- **Paradox:** Stock UP 41% from Jan 30 levels despite weak results
- **Today:** Trading UP 2.6% (likely on UAE expansion news, not fundamentals)
- **Analysis:** Market hasn't fully digested revenue/margin decline - presents SELL opportunity

---

## ‚ö†Ô∏è UPDATED: SHOULD YOU HOLD OR BOOK PROFITS? (Feb 6, 2026)

### Your Current Situation:
- **Entry:** ‚Çπ3,017.56 avg (70 shares)
- **CMP:** ‚Çπ4,260.10 (as of Feb 6, 2026)
- **Gain:** **+41.2% (‚Çπ86,978 total profit)**
- **Day Change:** +2.6% despite weak Q3 results

### **UPDATED Decision Framework (Feb 6, 2026):**

#### **Critical Context:**
- You're up **41% in ~1 month** (from ‚Çπ3,017 to ‚Çπ4,260)
- Q3 results show **revenue DECLINING -1.6% YoY** (not growing)
- **Margin compression:** EBITDA 18.9% vs historical 22%+
- Stock trading UP 2.6% today **despite weak results** (disconnect = opportunity)

---

#### **Scenario 1: Value Investor Approach (RECOMMENDED)**
‚Üí **ACTION: SELL 50% NOW, HOLD 50% WITH STOP-LOSS**

**Why Book Partial Profits?**
1. **41% gain in 1 month** - exceptional, unlikely to sustain
2. **Revenue declining** - Contradicts your expectation of "revenue increase"
3. **Margin compression** for 3 quarters - not just seasonality
4. **Market inefficiency** - Stock UP despite bad news = sell opportunity
5. **Risk management** - Lock in ‚Çπ43,489 profit, protect capital

**Recommended Action:**
- **SELL 35 shares** at ‚Çπ4,250-4,300 = ‚Çπ1,49,103 (book ‚Çπ43,489 profit)
- **HOLD 35 shares** with GTT stop-loss at ‚Çπ3,800 (26% buffer from current)
- **Wait for Q4 results** (Apr-May 2026) - if revenue/margins don't recover, exit remaining

**Profit Breakdown:**
- Total shares: 70
- Sell 50%: 35 shares √ó ‚Çπ4,260 = ‚Çπ1,49,100
- Profit on 35 shares: (‚Çπ4,260 - ‚Çπ3,017.56) √ó 35 = ‚Çπ43,489 locked in ‚úÖ
- Remaining: 35 shares with free upside (original cost recovered)

---

#### **Scenario 2: Aggressive Hold (HIGHER RISK)**
‚Üí **ACTION: HOLD 100% BUT SET STRICT STOP-LOSS**

**Only if you believe:**
- Q3 weakness is purely seasonal (management claims)
- UAE expansion + D2C will offset revenue decline
- Q4 will show strong rebound (revenue >‚Çπ550 Cr, margin >20%)
- You can stomach 30% drawdown if wrong

**Hold Strategy:**
- GTT stop-loss at ‚Çπ3,600 (15% downside protection from current)
- Target: ‚Çπ4,800-5,000 if Q4 results strong
- **HIGH RISK:** If Q4 disappoints, stock could crash to ‚Çπ3,000-3,200

---

### **My Strong Recommendation: SELL 50% NOW** üî¥

**Why This Is the Right Move:**

1. **Fundamentals vs Price Disconnect:**
   - Revenue DOWN 1.6% but stock UP 41% = market hasn't digested reality
   - When market wakes up, correction likely

2. **Risk-Reward Changed:**
   - At ‚Çπ3,017 entry: Asymmetric upside (fair value play)
   - At ‚Çπ4,260 current: Limited upside, significant downside risk

3. **Margin of Safety Evaporated:**
   - Stock now trading at **51% premium** to base DCF (‚Çπ2,823)
   - P/E ~31x (based on declining earnings) vs 22x at entry

4. **Revenue Declining = Red Flag:**
   - You specifically asked if "revenue has increased" - it DECREASED
   - 3-quarter trend of contraction + margin pressure = structural concern

5. **Opportunity Cost:**
   - Lock in ‚Çπ43k profit, redeploy to better opportunities
   - Keep 35 shares for upside if thesis recovers

**What Could Go Wrong With Full Hold:**
- Q4 results confirm structural slowdown ‚Üí Stock corrects 25-30% to ‚Çπ3,000
- Market realizes revenue declining ‚Üí P/E re-rates from 31x to 22x = ‚Çπ3,200
- You'd regret not booking at ‚Çπ4,260 when you had the chance

**Exit Triggers for Remaining 35 Shares:**
- ‚úÖ Stop-loss hit at ‚Çπ3,800
- ‚ùå Q4 revenue <‚Çπ500 Cr or margin <18%
- ‚ùå FY27 guidance disappointing
- ‚úÖ Sell another 50% (17-18 shares) if stock rallies to ‚Çπ4,800+

---

### **‚ö†Ô∏è UPDATED Action Plan (Feb 6, 2026):**

**IMMEDIATE (TODAY/THIS WEEK):**
- üî¥ **SELL 35 shares** at market price ‚Çπ4,250-4,300
  - Lock in profit: ‚Çπ43,489
  - Recovered capital: ~‚Çπ1,05,614 (original investment on 35 shares)
- ‚úÖ **Place GTT stop-loss** for remaining 35 shares at ‚Çπ3,800
- üìä **Update investment journal** with sell transaction

**Post-Sale (Remaining 35 Shares):**
- **Monitor Q4 FY26 results** (Apr-May 2026)
- **Watch for:** Revenue >‚Çπ550 Cr, EBITDA margin >20%
- **Price alerts:** ‚Çπ3,800 (stop-loss) | ‚Çπ4,800 (partial exit if rallies)

**If Q4 Results Strong:**
- Hold remaining 35 shares for ‚Çπ5,000+ target
- Consider re-buying IF stock corrects to ‚Çπ3,200-3,400 with strong fundamentals

**If Q4 Results Weak:**
- Exit remaining 35 shares on bounce to ‚Çπ4,000-4,200
- Do NOT hold beyond ‚Çπ3,800 stop-loss
- Redeploy capital to better opportunities

**Capital Redeployment (‚Çπ1.49L from sale):**
- Look for stocks with growing revenue + margins
- Avoid "valuation traps" like current GRWRHITECH situation

---

## üî¥ FINAL VERDICT (UPDATED FEB 6, 2026)

| Question | Answer |
|----------|--------|
| **Should you hold 100%?** | **NO** ‚ùå (Book 50% profit, fundamentals deteriorating) |
| **Should you book profits?** | **YES - PARTIAL** ‚úÖ (Sell 35 shares, lock ‚Çπ43k profit) |
| **Should you buy more?** | **ABSOLUTELY NOT** üö´ (Revenue declining, overvalued at ‚Çπ4,260) |
| **Risk-Reward?** | **UNFAVORABLE** (Limited upside, high downside from current level) |
| **Time Horizon?** | **Book now, reassess Q4** (Apr-May 2026) |
| **Confidence Level?** | **MEDIUM** (Fundamentals weakening vs price strength) |

### **Action Summary:**
1. ‚úÖ **SELL 35 shares** at market (‚Çπ4,250-4,300)
2. ‚úÖ **Place GTT stop-loss** for remaining 35 shares at ‚Çπ3,800
3. ‚è≥ **Monitor Q4 results** (Apr-May 2026)
4. üîç **Reassess** if revenue/margins recover in Q4

---

## DISCLAIMER

This analysis is for educational purposes only and not investment advice. The author is not a SEBI-registered advisor. The assumptions (DCF, growth rates, valuations) are opinions and may not materialize. Past performance does not guarantee future returns. **Do your own due diligence** before investing. Consult a qualified financial advisor for personalized advice.

**Key Uncertainties:**
- US tariff policy (binary risk)
- Q4 FY25 execution (seasonality vs structural issue?)
- TPU line success (FY27 margin expansion thesis)
- China competition (dumping risk)

**Monitor these quarterly. Adjust thesis as facts change. Good luck! üöÄ**

---

**Analysis Completed:** February 6, 2026  
**Next Review:** Post Q4 FY25 Results (Expected: Feb 2026)
